A combination of two human monoclonal antibodies cures symptomatic rabies - Institut Pasteur Access content directly
Journal Articles EMBO Molecular Medicine Year : 2020

A combination of two human monoclonal antibodies cures symptomatic rabies

Andrea Minola
  • Function : Author
Fabrizia Zatta
  • Function : Author
Davide Corti
  • Function : Author

Abstract

Rabies is a neglected disease caused by a neurotropic Lyssavirus, transmitted to humans predominantly by the bite of infected dogs. Rabies is preventable with vaccines or proper post-exposure prophylaxis (PEP), but it still causes about 60,000 deaths every year. No cure exists after the onset of clinical signs, and the case-fatality rate approaches 100% even with advanced supportive care. Here, we report that a combination of two potent neutralizing human monoclonal antibodies directed against the viral envelope glycoprotein cures symptomatic rabid mice. Treatment efficacy requires the concomitant administration of anti-bodies in the periphery and in the central nervous system through intracerebroventricular infusion. After such treatment, recovered mice presented good clinical condition, viral loads were undetectable, and the brain inflammatory profile was almost normal. Our findings provide the unprecedented proof of concept of an antibody-based therapeutic approach for symptomatic rabies.
Fichier principal
Vignette du fichier
A combinatio n of two human monoclonalantibodies cures symptomatic rabies.pdf (2.05 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

pasteur-02983042 , version 1 (29-10-2020)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Guilherme Dias de Melo, Florian Sonthonnax, Gabriel Lepousez, Grégory Jouvion, Andrea Minola, et al.. A combination of two human monoclonal antibodies cures symptomatic rabies. EMBO Molecular Medicine, 2020, pp.e12628. ⟨10.15252/emmm.202012628⟩. ⟨pasteur-02983042⟩
103 View
112 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More